EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Beijing Biostar Pharms Co Ltd (2563) fair value: what the stock is really worth

As of Sep 30, 2026: fair value of Beijing Biostar Pharms Co Ltd HK$1.67, price HK$4.83, upside -65.4%, quality 45 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · HK

BB Thin data Sep 27, 2026

Beijing Biostar Pharms Co Ltd

2563 · HK

Weakest SetupStrongly overvalued and low quality.

!Fair value HK$1.67 · Strongly overvalued (−65.4%)
!Quality 45/100
!Weak Growth (revenue 3y −0.2 %/yr)
!negative free cash flow
!Mixed vs. peers (3/7)
!Narrow moat 0/100
!Evidence only low, so the estimate is less certain
Watch Beijing Biostar Pharms Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$35.45 HK$2.63 Fair Value HK$1.67 Oct 2024 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

23‑month range HK$2.63 – HK$35.45 · fair‑value band HK$1.10 – HK$2.09 · the HK$4.83 price screens above the HK$1.67 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.

Follow Beijing Biostar Pharms Co in your weekly email

Every Wednesday you see whether Beijing Biostar Pharms Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Beijing Biostar Pharmaceuticals Co., Ltd., a synthetic biology-driven biopharmaceutical company, engages in the development, manufacturing, and commercialization of oncology products in the People's Republic of China.

Show more

Beijing Biostar Pharmaceuticals Co., Ltd., a synthetic biology-driven biopharmaceutical company, engages in the development, manufacturing, and commercialization of oncology products in the People's Republic of China. The company develops Utidelone injections for metastatic breast cancer, breast cancer neoadjuvant, non-small cell lung cancer, pancreatic cancer, non-small cell lung cancer brain metastasis, and breast cancer brain metastasis indications; and Utidelone capsules for metastasis breast cancer, triple-negative breast cancer adjuvant intensive, first line gastric cancer, platinum-resistant ovarian cancer, and soft tissue sarcoma indications. It is also involved in the development of Utidelone antibody drug conjugate in preclinical studies; and BG22, BG18, and BG44 products for solid tumor indications in preclinical studies. Beijing Biostar Pharmaceuticals Co., Ltd. was incorporated in 2002 and is headquartered in Beijing, China.

Stock analysis

Beijing Biostar Pharms Co Ltd (2563) currently trades at HK$4.83, while our model-based Fair Value estimate is HK$1.67, 65.4% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 3 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: HK$1.10 (bear) to HK$2.09 (bull), the price of HK$4.83 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Beijing Biostar Pharms Co Ltd reported revenue of 37.1M CNY in FY2025 versus 107M CNY in FY2021, a compound −23.2%/yr. Reported net income was −143M CNY in FY2025.

Key figures

Market cap HK$1.8B (≈ $225M) · P/S ratio 41.5 · EPS (TTM) HK$−0.1500 · Return on equity −18.0% · Return on assets (EBIT) −23.0% · Operating margin −422% · Revenue (TTM) 33.4M CNY · Revenue growth (YoY) −52.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 46% below its 52-week high and 84% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −65%, 2563 screens richer than that median.

Fair Value models

Bear HK$1.10 Fair Value HK$1.67 Bull HK$2.09
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) HK$1.19 HK$1.59 HK$2.37 50
All 1 models by family
Asset-Based
NCAV (Graham) HK$1.19 HK$1.59 HK$2.37 50

Open the full fair value analysis →

Notify me when 2563 reaches fair value

Put 2563 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 45/100

Of which business quality 48 · Market factors (momentum, volatility) 28

Profitability 1
Margins and returns on capital today
Quality Growth 35
Are margins and returns improving?
Cashflow 15
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 74
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 53
Price trend over the last 3–12 months (market factor)
52W Momentum 18
Distance to the 52-week high (market factor)
Net Issuance 81
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 4/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−52.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−385.5% (2021) → −407.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

2563 screens overvalued: fair value 65% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Beijing Biostar Pharms Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 638 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 45 · Above median
Fair Value upside −65.4% · Below median
Profitability
Return on assets −10.3% · Below median
Growth and dividend
Revenue growth −52.1% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.30× · Cheapest 25%
P/S (TTM) 6.74× · Pricier than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$176.95 A$194.65 +10%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Beijing Biostar Pharms Co Ltd · Fair Value
HK$1.67 −65%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Beijing Biostar Pharms Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2563

Frequently asked questions

Is Beijing Biostar Pharms Co Ltd (2563) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of HK$1.67 versus a price of HK$4.83, about −65% upside (overvalued).
What is the fair value of 2563?
Our model-based fair value for Beijing Biostar Pharms Co Ltd is HK$1.67 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$4.83.
What is the quality score of 2563?
Beijing Biostar Pharms Co Ltd has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Beijing Biostar Pharms Co Ltd (2563)?
Our model-based price target is the fair value of HK$1.67 (as of Sep 27, 2026) from 1 valuation models. Cautious scenario HK$1.10, optimistic scenario HK$2.09. It is a calculation from audited fundamentals, not an analyst target.
What is the Beijing Biostar Pharms Co Ltd stock forecast for 2026?
Our models put fair value at HK$1.67, about −65% upside versus a price of HK$4.83 (overvalued). Cautious scenario HK$1.10, optimistic scenario HK$2.09. The calculation is refreshed regularly with new filings.
What is the revenue of Beijing Biostar Pharms Co Ltd (2563)?
Beijing Biostar Pharms Co Ltd reported trailing-twelve-month revenue of about 33.4M CNY (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Beijing Biostar Pharms Co Ltd (2563)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Beijing Biostar Pharms Co Ltd it is HK$1.67 per share (as of Sep 27, 2026), against a price of HK$4.83. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Beijing Biostar Pharms Co Ltd stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 2563 trades above its calculated fair value: price HK$4.83, fair value HK$1.67, a gap of about −65% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2563?
No. The price is what the market pays today (HK$4.83); the fair value is what the company's own numbers justify (HK$1.67). For Beijing Biostar Pharms Co Ltd the two are HK$3.16 per share apart. That gap is exactly why we show both numbers side by side.
How much is Beijing Biostar Pharms Co Ltd worth?
The market values Beijing Biostar Pharms Co Ltd at about HK$1.8B (market capitalisation, as of Sep 27, 2026). Per share that is HK$4.83; our models calculate a fair value of HK$1.67 per share.
What do the bullish and bearish scenarios say about 2563?
Our models span a range for Beijing Biostar Pharms Co Ltd: cautious scenario HK$1.10, base HK$1.67, optimistic HK$2.09 per share (as of Sep 27, 2026, price HK$4.83). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Beijing Biostar Pharms Co Ltd (2563)?
Balance-sheet figures for Beijing Biostar Pharms Co Ltd (as of Sep 27, 2026): return on equity −18.0%. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is 2563 from its 52-week high?
Beijing Biostar Pharms Co Ltd trades at HK$4.83, about 46% below its 52-week high of HK$8.93 and 84% above the low of HK$2.63 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$1.67 is for.
Which stocks are comparable to Beijing Biostar Pharms Co Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Beijing Biostar Pharms Co Ltd stock attractive at the current price?
The data as of Sep 27, 2026: price HK$4.83, calculated fair value HK$1.67 (−65%), Quality Score 45/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2563 calculated?
We run Beijing Biostar Pharms Co Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$1.67, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. Beijing Biostar Pharms Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Beijing Biostar Pharms Co Ltd (2563)?
The closing price on Sep 30, 2026 was HK$4.83. Our model-based fair value is HK$1.67, about −65% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Beijing Biostar Pharms Co Ltd right now?
The price sits above even our optimistic bull case (HK$2.09). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (45/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (HK$1.10 to HK$2.09) leaves room in how you read the outcome.

Key figures of Beijing Biostar Pharms Co Ltd

How large is the market capitalisation of Beijing Biostar Pharms Co Ltd (2563)?
The market capitalisation of Beijing Biostar Pharms Co Ltd is HK$1.8B (≈ $225M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Beijing Biostar Pharms Co Ltd (2563)?
The price-to-sales ratio of Beijing Biostar Pharms Co Ltd is 41.5 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Beijing Biostar Pharms Co Ltd (2563)?
Earnings per share at Beijing Biostar Pharms Co Ltd are HK$−0.1500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Beijing Biostar Pharms Co Ltd (2563)?
The return on equity (ROE) of Beijing Biostar Pharms Co Ltd is −18.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Beijing Biostar Pharms Co Ltd (2563)?
On an EBIT basis the return on assets of Beijing Biostar Pharms Co Ltd is −23.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Beijing Biostar Pharms Co Ltd (2563)?
The operating margin of Beijing Biostar Pharms Co Ltd is −422% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Beijing Biostar Pharms Co Ltd (2563)?
Revenue at Beijing Biostar Pharms Co Ltd is growing −52.1% versus a year earlier (3y avg −0.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Beijing Biostar Pharms Co Ltd (2563) generate?
The free cash flow of Beijing Biostar Pharms Co Ltd is −175M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Beijing Biostar Pharms Co Ltd (2563) hold?
Beijing Biostar Pharms Co Ltd holds more cash than debt, 506M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Beijing Biostar Pharms Co Ltd in the live analysis

One click puts Beijing Biostar Pharms Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.